Center for Primary Health Care Research, Wallenberglaboratoriet, Lund University/Region Skåne, Inga-Marie Nilssons gata 53, plan 6, Box 50332, 202 13, Malmö, Sweden.
Department of Family Medicine and Community Health, Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai, New York, USA.
Clin Epigenetics. 2019 Feb 13;11(1):28. doi: 10.1186/s13148-019-0627-z.
Patients with unprovoked first venous thromboembolism (VTE) are at a high risk of recurrence. Although circulating microRNAs (miRNAs) have been found to be associated with VTE and are markers of hypercoagulability, this study is the first to examine whether circulating miRNAs are associated with the risk of VTE recurrence.
A nested case-control study design was used where plasma samples were obtained from 78 patients with unprovoked VTE from the Malmö Thrombophilia Study (MATS). A total of 39 VTE patients with recurrent VTE (cases) were matched with 39 VTE patients without recurrent VTE (controls) defined by age and sex (MATS population). Plasma levels of 179 different miRNAs were evaluated in the 78 samples (after anticoagulant treatment was stopped) using qPCR. A total of 110 miRNAs were detected in all samples. Among those, 12 miRNAs (miR-15b-5p, miR-106a-5p, miR-197-3p, miR-652-3p, miR-361-5p, miR-222-3p, miR-26b-5p, miR-532-5p, miR-27b-3p, miR-21-5p, miR-103a-3p, and miR-30c-5p) were found to be associated with recurrent VTE after multiple correction test and conditional logistic regression analysis. A further analysis showed that miR-15b-5p, miR-197-3p, miR-27b-3p, and miR-30c-5p exhibited a trend over time, with a larger difference in miRNA levels between cases and controls for earlier recurrence. Of these 12 miRNAs, 8 miRNAs significantly correlated with circulating transforming growth factor β1/2 (TGFβ1/2). Three of them correlated with platelet count.
We have identified 12 plasma miRNAs that may have the potential to serve as novel, non-invasive predictive biomarkers for VTE recurrence.
无诱因首发静脉血栓栓塞症(VTE)患者存在较高的复发风险。虽然循环 microRNAs(miRNAs)已被发现与 VTE 相关,并且是高凝状态的标志物,但这项研究是首次探讨循环 miRNAs 是否与 VTE 复发风险相关。
采用巢式病例对照研究设计,从马尔默血栓形成研究(MATS)中获取 78 例无诱因 VTE 患者的血浆样本。共有 39 例 VTE 复发患者(病例)和 39 例无复发 VTE 患者(对照)按年龄和性别与 78 例患者相匹配(MATS 人群)。使用 qPCR 检测了 78 例样本(在停止抗凝治疗后)中 179 种不同 miRNAs 的血浆水平。所有样本中检测到 110 种 miRNAs。其中,12 种 miRNAs(miR-15b-5p、miR-106a-5p、miR-197-3p、miR-652-3p、miR-361-5p、miR-222-3p、miR-26b-5p、miR-532-5p、miR-27b-3p、miR-21-5p、miR-103a-3p 和 miR-30c-5p)经多次校正检验和条件逻辑回归分析后与 VTE 复发相关。进一步分析表明,miR-15b-5p、miR-197-3p、miR-27b-3p 和 miR-30c-5p 随着时间的推移呈趋势变化,病例组和对照组之间的 miRNA 水平差异较大,提示复发较早。在这 12 种 miRNAs 中,有 8 种 miRNAs 与循环转化生长因子β1/2(TGFβ1/2)显著相关。其中 3 种与血小板计数相关。
我们发现了 12 种血浆 miRNAs,它们可能具有作为 VTE 复发新型非侵入性预测生物标志物的潜力。